Wegovy Obesity Pill Hits Pharmacy Shelves Nationwide

The Wegovy obesity pill has officially launched, offering a new oral option for individuals seeking weight management. Previously only available as an injection, this new form became accessible at pharmacies across the United States starting Monday.

Key Launch Details of Wegovy Pill

Novo Nordisk announced that the Wegovy pill is now stocked nationwide. The initial dose is available, with higher doses expected by the end of the week. The Food and Drug Administration (FDA) approved this medication for obesity treatment on December 22.

Clinical Effectiveness

Clinical studies suggest the pill is highly effective. A study published in the New England Journal of Medicine reported that a 25-milligram Wegovy pill resulted in an average weight reduction of 13.6% over 64 weeks. In comparison, participants given a placebo experienced only a 2.2% weight loss.

• Estimated 16.6% weight reduction for patients adhering to treatment, calorie restriction, and exercise.
• Patients must take the pill on an empty stomach for optimal absorption.
• Common side effects include nausea, diarrhea, and vomiting.

Cost and Insurance Information

Pricing for the Wegovy pill varies. The starting monthly cost for patients not using insurance is set at $149. Higher doses will be priced at $299 per month. For those with insurance, the medication can be procured for as little as $25 a month.

The list price, which pertains to insurance coverage, remains at $1,349 monthly, similar to the Wegovy injection. It is noteworthy that the availability of insurance coverage for obesity medications became more restricted in 2025, according to GoodRx analysis.

Competition and Future Developments

The Wegovy pill marks a significant advance as the first FDA-approved oral obesity treatment. Novo Nordisk’s Rybelsus for Type 2 diabetes, which contains the same active ingredient, semaglutide, is also on the market.

Eli Lilly is developing a competing obesity pill called Zepbound and applied for FDA approval in late 2025. A priority review voucher indicates a decision could be made soon.

The Wegovy pill offers hope for those struggling with obesity, combining efficacy with an easy-to-take format. As the market evolves, the availability of options will increase, potentially aiding more individuals in their weight loss journeys.